Sunbelt Securities Inc. Has $1.19 Million Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Sunbelt Securities Inc. cut its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 36.2% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 10,650 shares of the biopharmaceutical company's stock after selling 6,030 shares during the quarter. Sunbelt Securities Inc.'s holdings in Gilead Sciences were worth $1,193,000 at the end of the most recent quarter.

Other institutional investors also recently made changes to their positions in the company. Tsfg LLC boosted its stake in Gilead Sciences by 97.3% during the 1st quarter. Tsfg LLC now owns 1,298 shares of the biopharmaceutical company's stock valued at $145,000 after acquiring an additional 640 shares during the last quarter. 3Chopt Investment Partners LLC bought a new position in Gilead Sciences during the 1st quarter valued at $2,111,000. Mirae Asset Global Investments Co. Ltd. boosted its stake in Gilead Sciences by 18.5% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 514,638 shares of the biopharmaceutical company's stock valued at $57,531,000 after acquiring an additional 80,473 shares during the last quarter. Achmea Investment Management B.V. boosted its holdings in Gilead Sciences by 60.1% in the first quarter. Achmea Investment Management B.V. now owns 401,212 shares of the biopharmaceutical company's stock worth $44,956,000 after purchasing an additional 150,624 shares during the period. Finally, Waverton Investment Management Ltd acquired a new position in Gilead Sciences in the first quarter worth $224,000. 83.67% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts have commented on GILD shares. Needham & Company LLC reaffirmed a "hold" rating on shares of Gilead Sciences in a report on Wednesday, May 21st. Oppenheimer cut their target price on Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating on the stock in a research note on Friday, April 25th. Wells Fargo & Company raised their target price on Gilead Sciences from $120.00 to $140.00 and gave the company an "overweight" rating in a research note on Wednesday, March 5th. JPMorgan Chase & Co. upped their price objective on shares of Gilead Sciences from $120.00 to $130.00 and gave the stock an "overweight" rating in a report on Thursday, March 27th. Finally, Bank of America upped their price objective on shares of Gilead Sciences from $116.00 to $126.00 and gave the stock a "buy" rating in a report on Wednesday, March 5th. Nine investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $110.55.

Insider Buying and Selling at Gilead Sciences

In other news, insider Johanna Mercier sold 3,000 shares of the stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $110.17, for a total value of $330,510.00. Following the completion of the sale, the insider now directly owns 120,168 shares of the company's stock, valued at approximately $13,238,908.56. This represents a 2.44% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $110.17, for a total value of $275,425.00. Following the completion of the sale, the chief financial officer now directly owns 165,110 shares of the company's stock, valued at $18,190,168.70. This represents a 1.49% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 48,500 shares of company stock valued at $5,236,245 in the last 90 days. 0.27% of the stock is currently owned by insiders.

Gilead Sciences Stock Up 2.8%

NASDAQ GILD traded up $3.05 during trading on Friday, reaching $110.67. The company's stock had a trading volume of 19,541,254 shares, compared to its average volume of 7,682,147. The company has a current ratio of 1.37, a quick ratio of 1.23 and a debt-to-equity ratio of 1.16. The stock has a market capitalization of $137.67 billion, a PE ratio of 14.30, a PEG ratio of 0.72 and a beta of 0.29. The business has a 50-day moving average price of $106.39 and a 200-day moving average price of $103.35. Gilead Sciences, Inc. has a 1-year low of $66.01 and a 1-year high of $119.96.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, topping the consensus estimate of $1.77 by $0.04. The firm had revenue of $6.67 billion for the quarter, compared to the consensus estimate of $6.77 billion. Gilead Sciences had a net margin of 20.76% and a return on equity of 51.93%. The business's quarterly revenue was down .3% on a year-over-year basis. During the same quarter last year, the firm posted ($1.32) EPS. On average, research analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, June 27th. Shareholders of record on Friday, June 13th were issued a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a yield of 2.86%. The ex-dividend date was Friday, June 13th. Gilead Sciences's dividend payout ratio (DPR) is currently 66.53%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.